HLN
Price
$10.20
Change
-$0.07 (-0.68%)
Updated
Oct 26 closing price
Capitalization
44.86B
2 days until earnings call
Intraday BUY SELL Signals
TAK
Price
$20.43
Change
+$0.19 (+0.94%)
Updated
Oct 26 closing price
Capitalization
65.24B
2 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HLN vs TAK

HLN vs TAK Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
HLN vs. TAK commentary
Oct 27, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HLN is a Buy and TAK is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for HLN with price predictions
Oct 26, 2026

Momentum Indicator for HLN turns positive, indicating new upward trend

HLN saw its Momentum Indicator move above the 0 level on October 08, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 72 similar instances where the indicator turned positive. In 42 of the 72 cases, the stock moved higher in the following days. The odds of a move higher are at 58%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for HLN just turned positive on October 08, 2026. Looking at past instances where HLN's MACD turned positive, the stock continued to rise in 19 of 35 cases over the following month. The odds of a continued upward trend are 54%.

HLN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HLN crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 33%.

Following a +0.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where HLN advanced for three days, in 138 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 53%.

Bearish Trend Analysis

The 10-day RSI Indicator for HLN moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 14 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for HLN moved below the 200-day moving average on September 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.

HLN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HLN entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. HLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.738) is normal, around the industry mean (8.413). P/E Ratio (27.869) is within average values for comparable stocks, (-1.728). Projected Growth (PEG Ratio) (2.158) is also within normal values, averaging (2.152). Dividend Yield (0.025) settles around the average of (0.047) among similar stocks. P/S Ratio (2.739) is also within normal values, averaging (178.797).

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

A.I.Advisor
a Summary for TAK with price predictions
Oct 26, 2026

TAK in upward trend: price rose above 50-day moving average on October 06, 2026

TAK moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 18 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 51%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on TAK as a result. In 43 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.

The Moving Average Convergence Divergence (MACD) for TAK just turned positive on October 14, 2026. Looking at past instances where TAK's MACD turned positive, the stock continued to rise in 19 of 43 cases over the following month. The odds of a continued upward trend are 44%.

Following a +3.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where TAK advanced for three days, in 156 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.

The Aroon Indicator entered an Uptrend today. In 104 of 273 cases where TAK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 38%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 44%.

TAK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.009) is normal, around the industry mean (8.413). P/E Ratio (-0.391) is within average values for comparable stocks, (-1.728). Projected Growth (PEG Ratio) (0.425) is also within normal values, averaging (2.152). Dividend Yield (0.057) settles around the average of (0.047) among similar stocks. P/S Ratio (1.968) is also within normal values, averaging (178.797).

The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. TAK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

FUNDAMENTALS RATINGS
TAK: Fundamental Ratings
TAK
OUTLOOK RATING
1..100
40
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
PROFIT vs RISK RATING
1..100
29
SMR RATING
1..100
91
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
HLNTAK
RSI
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
41%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
40%
Momentum
ODDS (%)
Bullish Trend 1 day ago
58%
Bullish Trend 1 day ago
45%
MACD
ODDS (%)
Bullish Trend 1 day ago
54%
Bullish Trend 1 day ago
44%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
53%
Bullish Trend 1 day ago
47%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
52%
Bullish Trend 1 day ago
49%
Advances
ODDS (%)
Bullish Trend 7 days ago
53%
Bullish Trend 11 days ago
49%
Declines
ODDS (%)
Bearish Trend 1 day ago
53%
Bearish Trend 14 days ago
44%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
48%
Bearish Trend 1 day ago
42%
Aroon
ODDS (%)
Bearish Trend 1 day ago
48%
Bullish Trend 4 days ago
38%
COMPARISON
Comparison
Oct 27, 2026
Stock price -- (HLN: $10.20 vs. TAK: $20.43)
Brand notoriety: HLN and TAK are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HLN: 88% vs. TAK: 95%
Market capitalization -- HLN: $44.86B vs. TAK: $65.24B
HLN [@Pharmaceuticals: Generic] is valued at $44.86B. TAK’s [@Pharmaceuticals: Generic] market capitalization is $65.24B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HLN’s FA Score shows that 1 FA rating(s) are green while TAK’s FA Score has 2 green FA rating(s).

  • HLN’s FA Score: 1 green, 4 red.
  • TAK’s FA Score: 2 green, 3 red.
According to our system of comparison, TAK is a better buy in the long-term than HLN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HLN’s TA Score shows that 5 TA indicator(s) are bullish while TAK’s TA Score has 5 bullish TA indicator(s).

  • HLN’s TA Score: 5 bullish, 6 bearish.
  • TAK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, TAK is a better buy in the short-term than HLN.

Price Growth

HLN (@Pharmaceuticals: Generic) experienced а +0.59% price change this week, while TAK (@Pharmaceuticals: Generic) price change was +4.18% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.57%. For the same industry, the average monthly price growth was -11.91%, and the average quarterly price growth was +7.55%.

Reported Earning Dates

HLN is expected to report earnings on Oct 29, 2026.

TAK is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.57% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
HLN
Daily Signal:
Gain/Loss:
TAK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ESP53.041.02
+1.96%
Espey Mfg & Electronics Corp
WLKP21.13-0.02
-0.09%
Westlake Chemical Partners LP
XYL108.24-0.50
-0.46%
Xylem
INTA47.15-0.84
-1.75%
Intapp
CDLX1.65-0.15
-8.33%
Cardlytics